Prevention of fetal adrenergic signaling improves metabolic dysfunction in IUGR

预防胎儿肾上腺素能信号传导可改善 IUGR 的代谢功能障碍

• 批准号: 9013470
• 负责人: SEAN W LIMESAND
• 金额: $ 43.69万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-15 至 2019-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9013470
• 关键词: Adrenal Glands; Adrenergic Agents; Adult; Adverse effects; Barker Hypothesis; Beta Cell; Bilateral; Blood Glucose; Catecholamines; Cell Respiration; Cells; Chronic; Clinical; Coupling; Data; Dependence; Development; Diabetes Mellitus; Dietary Intervention; Epidemiology; Epinephrine; Fatty Acids; Fetal Growth; Fetal Growth Retardation; Fetal Tissues; Fetus; Functional disorder; Glucose; Glucose Intolerance; Glycolysis; Growth; Health; Hypoglycemia; Hypoxemia; In Vitro; Incidence; Individual; Infant; Infusion procedures; Insulin; Intervention; Islets of Langerhans; Knowledge; Left; Longevity; Longitudinal Studies; Measures; Mediating; Medical; Metabolic; Metabolic Diseases; Metabolism; Methods; Mitochondria; Muscle; Muscle Mitochondria; Newborn Infant; Non-Insulin-Dependent Diabetes Mellitus; Norepinephrine; Nutrient; Outcome; Oxidative Phosphorylation; Oxygen; Pattern; Perinatal mortality demographics; Placental Insufficiency; Plasma; Predisposition; Pregnancy; Premature Birth; Prevention; Production; Publishing; Reactive Oxygen Species; Regulation; Reporting; Respiration; Risk; Role; Sheep; Signal Transduction; Site; Skeletal Muscle; Stress; Supplementation; Testing; Therapeutic; Tissues; Toxic effect; UCP2 protein; Work; adrenergic block; aerobic glycolysis; base; beta-2 Adrenergic Receptors; beta-adrenergic receptor; blood glucose regulation; desensitization; effective therapy; exome sequencing; fetal; flexibility; glucose disposal; glucose metabolism; imprint; improved; in vivo; innovation; insulin secretion; insulin sensitivity; islet; muscle metabolism; novel; novel strategies; oxidation; perinatal morbidity; prenatal stress; programs; research study; response

 DESCRIPTION (provided by applicant): Intrauterine growth restriction (IUGR) causes perinatal morbidity and mortality. Furthermore, epidemiological evidence shows that surviving IUGR infants are at greater risk of developing glucose intolerance and diabetes during their life span. Nutritional interventions for IUGR have raised concerns for fetal toxicity leaving few therapeutic options available aside from close fetal surveillance to indicate preterm delivery. However, previous strategies to provide exogenous nutrients failed to reduce fetal catecholamine concentrations. In the IUGR fetus, low blood glucose and oxygen concentrations are prevalent and elevate fetal plasma norepinephrine and epinephrine in the final trimester. Administered alone, catecholamines restrict fetal growth in part via action on islets to inhibit insulin secretion. Additionally, our findings also indicate that chronic elevations in catecholamines increase glucose utilization rates yet decrease insulin stimulated glucose oxidation rates in skeletal muscle. Preliminary findings show chronic adrenergic stimulation reduces uncoupling protein 2 (UCP2) in semitendinosus muscle, which makes myofibers dependent on glycolysis. Experiments performed to characterize catecholamine mediated suppression of insulin secretion in IUGR fetuses revealed hyper-insulin secretion after chronic catecholamine exposure. In vitro studies confirmed these findings result from chronic catecholamines, but not from IUGR alone. This adrenergic programming was intrinsic to ß-cells, in which exome sequencing identified decreased UCP2 expression. Based on these findings, we formulated the hypothesis that chronic adrenergic stimulation promotes glycolysis and inhibits oxidative metabolism in IUGR fetuses through ß2-adrenergic desensitization and reductions in UCP2. Furthermore, these effects explain glucose dependence in muscle, enhanced insulin secretion in islets, and ultimately further reductions in fetal growth. In aim 1 w will measure the effects of chronic adrenergic action in IUGR fetuses by quantifying insulin stimulated glucose metabolism in fetuses with a bilateral adrenal demedullation or sustained norepinephrine infusions. In aim 2 we will determine the role for UCP2 suppression by catecholamines. Mechanisms will be examined for increased glucose-stimulated insulin secretion in IUGR islets and disrupted metabolic flexibility in IUGR myofibers. Finally, we will assess an intervention strategy of administration of both oxygen and glucose to reduce plasma catecholamines in IUGR fetuses. By alleviating adrenergic signaling and providing glucose, a major nutrient for fetal oxidative metabolism, we expect that insulin mediated glucose disposal will be normalized in IUGR fetuses. Collectively, the proposed work will provide fundamental new knowledge about how chronic adrenergic stimulation reduces fetal growth through persistent metabolic programing adaptations. Furthermore, we will explore a practical method to reverse high fetal catecholamines via maternal intervention, which has potent clinical importance for both short and long term improvements in IUGR outcomes.

 描述（由申请人提供）：宫内生长受限（IUGR）导致围产期发病率和死亡率。此外，流行病学证据表明，存活的IUGR婴儿在其一生中发生葡萄糖耐受不良和糖尿病的风险更大。对IUGR的营养干预引起了对胎儿毒性的关注，除了密切监测胎儿以指示早产外，几乎没有治疗选择。然而，以前的策略，以提供外源性营养素未能降低胎儿儿茶酚胺浓度。在IUGR胎儿中，低血糖和低氧浓度是普遍的，并在最后三个月升高胎儿血浆去甲肾上腺素和肾上腺素。单独给药时，儿茶酚胺通过作用于胰岛抑制胰岛素分泌而部分限制胎儿生长。此外，我们的研究结果还表明，慢性升高的儿茶酚胺增加葡萄糖的利用率，但降低胰岛素刺激的葡萄糖氧化率在骨骼肌。初步研究结果表明，慢性肾上腺素能刺激减少半腱肌中的解偶联蛋白2（UCP 2），这使得肌纤维依赖于糖酵解。在IUGR胎儿中进行的表征儿茶酚胺介导的胰岛素分泌抑制的实验揭示了慢性儿茶酚胺暴露后的高胰岛素分泌。体外研究证实，这些发现是由慢性儿茶酚胺引起的，而不是单独由IUGR引起的。这种肾上腺素能编程是β细胞固有的，其中外显子组测序鉴定出UCP 2表达降低。基于这些发现，我们提出了一个假说，即慢性肾上腺素能刺激通过β 2-肾上腺素能脱敏和UCP 2减少促进IUGR胎儿糖酵解并抑制氧化代谢。此外，这些效应解释了肌肉中的葡萄糖依赖性、胰岛中胰岛素分泌的增强以及最终胎儿生长的进一步减少。在目的1中，我们将通过定量双侧肾上腺脱髓鞘或持续输注去甲肾上腺素的胎儿中胰岛素刺激的葡萄糖代谢来测量IUGR胎儿中慢性肾上腺素能作用的影响。在目标2中，我们将确定UCP 2抑制的作用，由儿茶酚胺。将检查葡萄糖刺激胰岛素分泌增加的IUGR胰岛和IUGR肌纤维代谢灵活性破坏的机制。最后，我们将评估一个干预策略，管理氧气和葡萄糖，以减少血浆儿茶酚胺在IUGR胎儿。通过减轻肾上腺素能信号和提供葡萄糖，胎儿氧化代谢的主要营养物质，我们预计胰岛素介导的葡萄糖处置将在IUGR胎儿正常化。总的来说，拟议的工作将提供关于慢性肾上腺素能刺激如何通过持续的代谢编程适应降低胎儿生长的基本新知识。此外，我们将探索一种实用的方法，通过母亲干预来逆转高胎儿儿茶酚胺，这对IUGR结局的短期和长期改善具有潜在的临床意义。